Comments on reasons for third-party review pilot's unpopularity sought by FDA in letter to industry.
This article was originally published in The Gray Sheet
FDA SEEKING COMMENTS ON THIRD-PARTY REVIEW PILOT "LOW UTILIZATION" through a letter on the pilot sent to third parties and device trade groups during the week of Nov. 18. Calling for comments by Dec. 15, the agency asks respondents to discuss "factors that may account for the industry's low utilization of the pilot program to date."
You may also be interested in...
AMAG outlines plans for retrospective real-world evidence studies, and possibly a new placebo-controlled trial with a primary endpoint of preterm birth <32 weeks, in a filing opposing the Center for Drug Evaluation and Research’s proposal to withdraw the drug.
The leading Korean pharma firm’s oral, third-generation EGFR-TKI is approved in the country, providing a new option for patients with advanced NSCLC and increasing hopes for global approvals given an ongoing global Phase III combination trial led by partner J&J.
DePuy Synthes expects its Velys robotic-assisted system to be cost-effective, easy-to-use and to be well-suited for use in ambulatory surgery centers.